GlassScriptPhysician profile
James Paul Adamo
NPI 1194721993
$6,875.71
in general payments reported to CMS, 2019-2025
24 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $183 · 2021: $713 · 2022: $1,075 · 2023: $283 · 2024: $2,068 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,811 · Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,811.34 |
| Food and Beverage | $1,096.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $2,986.62 | 2022-2025 | Monarch |
| Ethicon INC. | $1,533.58 | 2019-2024 | Monarch Platform |
| Ekos Corporation | $720.27 | 2019 | |
| Noah Medical Corporation | $507.78 | 2025 | Galaxy |
| Penumbra, INC. | $349.12 | 2021-2022 | |
| Abbvie INC. | $124.55 | 2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $109.64 | 2019-2021 | |
| Boston Scientific Corporation | $98.08 | 2022 | |
| Pulmonx Corporation | $76.27 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Glaxosmithkline, LLC. | $46.46 | 2021-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $45.68 | 2022-2024 | Tagrisso, Fasenra |
| Portola Pharmaceuticals, LLC | $45.45 | 2020 | |
| Abiomed | $39.25 | 2021 | |
| Mylan Specialty L.P. | $23.41 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $22.36 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $21.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.31 | 2024 | Entyvio |
| Vapotherm INC | $17.50 | 2024 | Vapotherm |
| Insmed, INC. | $17.42 | 2021 | |
| Bioxcel Therapeutics, INC. | $16.77 | 2023 | Igalmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.93 | 2024 | Spiriva Respimat |
| Amgen INC. | $13.09 | 2024 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $12.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Adamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.